# Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis

> **NCT01569074** · PHASE2 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 163 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Fostamatinib
- **DRUG:** Fostamatinib
- **DRUG:** Fostamatinib
- **DRUG:** Fostamatinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01569074
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-04
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 163 (ACTUAL)
- **Why stopped:** AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to Rigel Pharmaceuticals.
- **Last updated:** 2014-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569074, "Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01569074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*